Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125254541 | 12525454 | 1 | I | 20160428 | 20160628 | 20160704 | 20160704 | EXP | US-ASTRAZENECA-2016SE72292 | ASTRAZENECA | 338.00 | DY | F | Y | 3.80000 | KG | 20160705 | MD | DE | DE |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125254541 | 12525454 | 1 | PS | SYNAGIS | PALIVIZUMAB | 1 | Intramuscular | 100 MG | U | U | 0 | INJECTION | |||||||
| 125254541 | 12525454 | 2 | SS | SYNAGIS | PALIVIZUMAB | 1 | Intramuscular | 100 MG | U | U | 0 | INJECTION | |||||||
| 125254541 | 12525454 | 3 | SS | SYNAGIS | PALIVIZUMAB | 1 | Intramuscular | 100 MG | U | U | 0 | INJECTION | |||||||
| 125254541 | 12525454 | 4 | SS | SYNAGIS | PALIVIZUMAB | 1 | Intramuscular | 100 MG | U | U | 0 | INJECTION | |||||||
| 125254541 | 12525454 | 5 | SS | SYNAGIS | PALIVIZUMAB | 1 | Intramuscular | 100 MG | U | U | 0 | INJECTION | |||||||
| 125254541 | 12525454 | 6 | C | ASPIRIN. | ASPIRIN | 1 | 0 | ||||||||||||
| 125254541 | 12525454 | 7 | C | SPIRONOLACTON | SPIRONOLACTONE | 1 | 0 | ||||||||||||
| 125254541 | 12525454 | 8 | C | FUROSEMID | FUROSEMIDE | 1 | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125254541 | 12525454 | 1 | Antiviral prophylaxis |
| 125254541 | 12525454 | 2 | Antiviral prophylaxis |
| 125254541 | 12525454 | 3 | Antiviral prophylaxis |
| 125254541 | 12525454 | 4 | Antiviral prophylaxis |
| 125254541 | 12525454 | 5 | Antiviral prophylaxis |
| 125254541 | 12525454 | 6 | Product used for unknown indication |
| 125254541 | 12525454 | 7 | Product used for unknown indication |
| 125254541 | 12525454 | 8 | Product used for unknown indication |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 125254541 | 12525454 | HO |
| 125254541 | 12525454 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125254541 | 12525454 | Bronchitis | |
| 125254541 | 12525454 | Oxygen consumption increased | |
| 125254541 | 12525454 | Respiratory syncytial virus infection |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 125254541 | 12525454 | 1 | 20151116 | 20151116 | 0 | |
| 125254541 | 12525454 | 2 | 20151211 | 20151211 | 0 | |
| 125254541 | 12525454 | 3 | 20160205 | 20160205 | 0 | |
| 125254541 | 12525454 | 4 | 20160304 | 20160304 | 0 | |
| 125254541 | 12525454 | 5 | 20160401 | 20160401 | 0 |